How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.
Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA.
Sehouli J, et al. Among authors: nasser s.
Int J Gynecol Cancer. 2024 Nov 4;34(11):1677-1684. doi: 10.1136/ijgc-2024-005982.
Int J Gynecol Cancer. 2024.
PMID: 39496422